Dianthus Therapeutics (DNTH) Equity Ratio (2017 - 2025)

Dianthus Therapeutics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.93 for Q4 2025.

• In Q4 2025, Equity Ratio fell 1.39% year-over-year to 0.93; the TTM figure through Dec 2025 stood at 0.93 (down 1.39% YoY), while the FY2025 annual figure was 0.93, down 1.39% from the prior year.
• Equity Ratio was 0.93 for Q4 2025 at Dianthus Therapeutics, down from 0.95 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2024 to a low of 0.78 in Q2 2023.
• Historically, Equity Ratio has averaged 0.48 across 5 years, with a median of 0.92 in 2021.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio tumbled 487.83% in 2022, then jumped 537.69% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.09 in 2021, then sank by 487.83% to 0.53 in 2022, then surged by 276.32% to 0.94 in 2023, then climbed by 0.12% to 0.94 in 2024, then dropped by 1.39% to 0.93 in 2025.
• The last three Equity Ratio figures came in at 0.93 (Q4 2025), 0.95 (Q3 2025), and 0.93 (Q2 2025), per Business Quant data.